CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin (GO), the combination of anti-CD33 antibody with anti-neoplastic agent calicheamicin, is currently the only ADC approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed and R/R CD33 + AML [142–144].